This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue


Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.




NUCALA: Sustained reduction in blood eosinophil levels without complete depletion5,6

Rapid reduction in blood eosinophil levels without complete depletion5,7

  1. *Data based on geometric mean with mepolizumab 75 mg IV (n=10) at first measurement post-dose from a phase 2 study in 70 adult patients with asthma and blood eosinophil count >200 cells/μL (mean baseline blood eosinophils: 348 cells/μL).5,6

The clinical significance of these pharmacodynamics data is unknown; MOA of mepolizumab in asthma has not been definitively established.


  1. Weller PF, Spencer LA. Functions of tissue-resident eosinophils. Nat Rev Immunol. 2017;17:746-757.
  2. Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med. 2005;172(2):149-160.
  3. Malinovschi A, Fonseca JA, Jacinto T, Alving K, Janson C. Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. J Allergy Clin Immunol. 2013;132(4):821-827 e5.
  4. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343-373.
  5. Data on file, GSK.
  6. Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143(5):1742-1751.
  7. Pouliquen IJ, Kornmann O, Barton SV, et al. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab. Int J Clin Pharmacol Ther. 2015;53(12):1015-1027.
  8. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicenter, double-blind, placebo-controlled trial. Lancet. 2012;380:651-659.